Novedades en la guía de práctica clínica de la Sociedad Europea de Cardiología en dislipemias: el peso de la evidencia

Abstract

The publication of pivotal clínical trials, such as the FOURIER and ODYSSEY OUTCOMES trials, and of other types of clínical study since 2016 has resulted in changes in the clínical practice guidelines for patients with dyslipidemias, which were updated in 2019. Cardiovascular risk stratification has been improved by the use of: (i) noninvasive cardiovascular imaging, involving for example the coronary calcium score, carotid or femoral artery ultrasonography, and coronary CT angiography; and (ii) biomarkers, particularly lipoprotein(a). However, the principle novelties were much stricter low-density lipoprotein cholesterol treatment targets and new recommendations on ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, added to statins, which have now become class-I treatment recommendations. Furthermore, the Spanish Society of Cardiology’s consensus on improving lipid control in secondary prevención provides a simple and practical way of optimizing lipid-lowering therapy.